Loading
A phase 2 trial of Trastuzumab rezetecan, SHR-A2102, Adebrelimab and Mecapegfilgrastim in Triple-negative breast cancer, run by Fudan University, now recruiting.
Reverse Triple Negative Immune Resistant Breast Cancer is a phase 2 interventional study registered as NCT05076682 by Fudan University, with 80 participants planned, started 2022-06-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline. Conditions recorded: Triple-negative Breast Cancer.
Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Triple-negative breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Mecapegfilgrastim and the tag pipeline.
Shares SHR-A2102, Adebrelimab and the tag pipeline.
Shares SHR-A2102, Adebrelimab and the tag pipeline.
Shares SHR-A2102, Adebrelimab and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares SHR-A2102, Adebrelimab and the tag pipeline.
Shares SHR-A2102, Adebrelimab and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Triple-negative breast cancer (TNBC) and the tag pipeline.